A digital view of the world illustrates how Astellas is a global company committed to serving patients worldwide.

News

Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.

Month Year

Month Year

Jul 1, 2015

Astellas Announces Status of Acquisition of Own Shares

(Under the provision of its Articles of Incorporation in accordance with Article 165, paragraph 2 of the Companies Act)

Read more about Astellas Announces Status of Acquisition of Own Shares
Jun 15, 2015

Results of Additional Analysis of Data from Japanese Clinical Trial of Anti-TNF-alpha Antibody Certolizumab Pegol Announced at 2015 EULAR Annual European Congress of Rheumatology

Read more about Results of Additional Analysis of Data from Japanese Clinical Trial of Anti-TNF-alpha Antibody Certolizumab Pegol Announced at 2015 EULAR Annual European Congress of Rheumatology
Jun 2, 2015

Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio established to develop products for Celiac Disease and Type 1 Diabetes -

Astellas Pharma Inc. (“Astellas”; TSE 4503, headquarters: Tokyo; President and CEO Yoshihiko Hatanaka) and Anokion SA (“Anokion“, headquarters: Lausanne; Chairman Jeffrey A. Hubbell) today...

Read more about Astellas and Anokion to Collaborate on Immune Tolerance Therapeutics - Kanyos Bio established to develop products for Celiac Disease and Type 1 Diabetes -
Jun 2, 2015

NEW ENZALUTAMIDE DATA IN TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT THE 2015 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING

TOKYO and NORTHBROOK, Ill. – June 1, 2015 – Astellas Pharma Inc. (Tokyo: 4503) announced that data from a Phase 2 study evaluating the investigational use of enzalutamide as a single agent for...

Read more about NEW ENZALUTAMIDE DATA IN TRIPLE-NEGATIVE BREAST CANCER PRESENTED AT THE 2015 AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
Jun 1, 2015

Astellas Announces Status of Acquisition of Own Shares

Read more about Astellas Announces Status of Acquisition of Own Shares
May 30, 2015

Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Read more about Astellas Announces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)
May 27, 2015

Strategic Plan 2015-2017

Building Resilience for Sustainable Growth

Read more about Strategic Plan 2015-2017
May 26, 2015

Astellas: Strategic Plan 2015-2017

Read more about Astellas: Strategic Plan 2015-2017
May 26, 2015

Announcement of Approval of Additional Indication for the TNF-α inhibitor Certolizumab Pegol (Generic Name) in Japan

Read more about Announcement of Approval of Additional Indication for the TNF-α inhibitor Certolizumab Pegol (Generic Name) in Japan
May 26, 2015

Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan

Read more about Astellas Receives Approval for a Supplemental New Drug Application for Irribow®/Irribow® OD, a Treatment of Diarrhea-predominant Irritable Bowel Syndrome, in Japan

Show per page

Discover more

Return to media homepage

Follow us

Subscribe to news alerts